Table 2.
Outcome of administering specific or non-specific anti-TNF agents in states exhibiting excess cerebral TNF and the opposing effects of TNF and anti-TNF agents of brain glutamate levels. See text for references
| Excess cerebral TNF present | Positive outcome after etanercept, etc. | Positive non-specific TNF inhibitors outcome | |||
|---|---|---|---|---|---|
| Thalid or dithio-thalid | Nilotinib | Cannabinoids | |||
| Alzheimer’s disease | + | + | + | + | + |
| Parkinson’s disease | + | ? | ? | + | + |
| Huntington’s disease | + | ? | ? | ? | ? |
| Amyotropic lateral sclerosis | + | + | ? | ? | ? |
| Septic encephalopathy | + | ? | ? | ? | ? |
| Traumatic brain injury | + | + | + | ? | + |
| Stroke | + | + | + | ? | ? |
| Poor post-operative cognition | + | + | ? | ? | ? |
| Poor post-chemother cognition | + | ? | ? | ? | ? |
| Poor post-irradiation cognition | + | ? | ? | ? | ? |
| Epileptic seizures | + | ? | ? | ? | + |
| HIV dementia | + | ? | ? | ? | + |
| Neurogenic pain | + | + | ? | ? | + |
| Viral encephalitides | + | ? | ? | ? | + |
| Elevated brain glutamate | + | ||||
| Lower brain glutamate | + | ? | ? | + |